Cerebrolysin
Cerebrolysin is a neuropeptide preparation derived from porcine brain proteins containing neurotrophic factors that mimic BDNF and NGF, extensively researched for Alzheimer's disease, stroke recovery, traumatic brain injury, and cognitive enhancement.
Cerebrolysin is a parenterally administered neuropeptide preparation consisting of low-molecular-weight peptides and free amino acids derived from purified porcine brain proteins. Developed by the Austrian pharmaceutical company EVER Neuro Pharma, Cerebrolysin contains biologically active peptides that exert neurotrophic effects similar to naturally occurring brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).
Overview
Cerebrolysin is produced through standardized enzymatic proteolysis of lipid-free porcine brain proteins, yielding a reproducible mixture containing approximately 25% low-molecular-weight biologically active neuropeptides and 75% free amino acids. The active peptide fraction includes fragments with structural and functional similarity to endogenous neurotrophic factors, including BDNF, NGF, GDNF (glial cell line-derived neurotrophic factor), and CNTF (ciliary neurotrophic factor).
Unlike recombinant neurotrophic factors, which are large proteins that do not cross the blood-brain barrier (BBB), the small peptides in Cerebrolysin readily cross the BBB, enabling peripheral administration with central nervous system effects. This pharmacokinetic advantage has made Cerebrolysin a practical candidate for neurological conditions where neurotrophic support is needed but direct CNS delivery is impractical.
Cerebrolysin has been the subject of over 200 clinical studies involving more than 70,000 patients, making it one of the most clinically documented neurotrophic agents available.
Mechanism of Action
Cerebrolysin exerts pleiotropic neurotrophic and neuroprotective effects through multiple convergent pathways:
- Neurotrophic signaling: The peptide fraction activates Trk (tropomyosin receptor kinase) signaling cascades, particularly TrkA and TrkB, mimicking the downstream effects of NGF and BDNF respectively. This activates PI3K/Akt and MAPK/ERK pathways that promote neuronal survival, axonal growth, and synaptic plasticity Rockenstein et al. (2006).
- Anti-apoptotic effects: Cerebrolysin inhibits calpain-mediated neuronal death and reduces caspase-3 activation, protecting neurons from apoptosis following ischemic or excitotoxic injury Hartbauer et al. (2001).
- Neuroplasticity enhancement: Cerebrolysin promotes dendritic branching, synaptogenesis, and long-term potentiation (LTP) — the cellular basis of learning and memory. It increases expression of synaptic proteins including synaptophysin and MAP-2 Windisch et al. (2006).
- Anti-inflammatory action: The preparation reduces microglial activation and suppresses pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in neuroinflammatory models, providing a neuroprotective anti-inflammatory milieu.
- Amyloid beta modulation: In Alzheimer's disease models, Cerebrolysin reduces amyloid beta production and deposition by modulating APP (amyloid precursor protein) processing, shifting it away from the amyloidogenic pathway Rockenstein et al. (2006).
- Oxidative stress reduction: Cerebrolysin enhances endogenous antioxidant defenses, including superoxide dismutase (SOD) and glutathione peroxidase activity, and reduces markers of oxidative damage in brain tissue.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Traumatic Brain Injury
Clinical trials in TBI have demonstrated that Cerebrolysin administration within 24 hours of injury can improve Glasgow Outcome Scale scores and reduce the duration of impaired consciousness. Chen et al. conducted a multicenter RCT in 130 TBI patients and found that 50 mL of daily IV Cerebrolysin for 30 days significantly improved clinical outcomes at 6 months compared to placebo Chen et al. (2013). Preclinical models suggest the mechanism involves reduction of cerebral edema, preservation of BBB integrity, and inhibition of secondary neuroinflammatory cascades.
Alzheimer's Disease
Cerebrolysin has been studied extensively in Alzheimer's disease (AD), with multiple randomized controlled trials demonstrating cognitive and functional improvements. A pivotal 24-week RCT by Alvarez et al. involving 279 patients with mild-to-moderate AD showed that Cerebrolysin (30 mL IV daily for 4 weeks, repeated after a 2-month wash-out) produced significant improvements in ADAS-cog scores compared to placebo, with benefits sustained for up to 3 months after treatment cessation Alvarez et al. (2006). Mechanistic studies in transgenic AD mouse models demonstrate that Cerebrolysin reduces amyloid plaque burden, tau hyperphosphorylation, and synaptic loss Rockenstein et al. (2006).
A Cochrane systematic review acknowledged that while several trials showed cognitive improvements, the overall evidence quality was variable and larger, more rigorous trials were recommended Wei et al. (2007).
Ongoing & Future Research
- E-COMPASS trial (NCT01363453): Large-scale evaluation of Cerebrolysin + alteplase in acute ischemic stroke
- Investigation of Cerebrolysin in Parkinson's disease dementia
- Biomarker-guided treatment optimization using serum BDNF and other neurotrophic markers as response predictors (Stan et al., DOI: 10.3390/jcm12031042)
- Research into Cerebrolysin for post-COVID neurological sequelae ("brain fog")
- Development of oral or intranasal neurotrophic peptide formulations inspired by Cerebrolysin's active fraction
- Studies on optimal treatment duration and cycling protocols for chronic neurodegenerative conditions
Vascular Dementia
Several clinical trials have evaluated Cerebrolysin in vascular dementia (VaD). A randomized, placebo-controlled trial by Guekht et al. in 242 patients with mild-to-moderate VaD showed that Cerebrolysin (20 mL IV daily for 24 weeks) produced significant improvements in ADAS-cog+ and CIBIC+ scores compared to placebo Guekht et al. (2011).
Cognitive Enhancement and Neuroplasticity
Beyond disease-specific applications, Cerebrolysin has been studied for its potential to enhance cognitive function in aging populations. Research demonstrates that Cerebrolysin increases synaptic density, enhances LTP, and improves spatial learning in aged rodent models. These findings suggest applications in age-related cognitive decline, though clinical evidence for cognitive enhancement in healthy individuals remains limited Windisch et al. (2006).
Stroke Recovery
Cerebrolysin has been investigated in multiple large-scale clinical trials for acute ischemic stroke. The CASTA (Cerebrolysin in Patients with Acute Ischemic Stroke in Asia) trial, involving 1,070 patients, evaluated Cerebrolysin (30 mL IV daily for 10 days) initiated within 12 hours of stroke onset. While the primary endpoint (NIHSS improvement at day 90) did not reach significance in the overall population, subgroup analysis showed significant benefit in patients with moderate-to-severe stroke (NIHSS >12) Heiss et al. (2012).
The CARS (Cerebrolysin and Recovery After Stroke) studies further demonstrated that Cerebrolysin enhances motor recovery and functional outcomes when combined with rehabilitation, with MRI evidence of increased neuroplasticity markers Muresanu et al. (2016).
Neurological/Immunological Mechanisms
Neurotrophic receptor signaling:
- Active peptide fraction activates TrkA (NGF receptor) and TrkB (BDNF receptor) signaling
- TrkA activation → Ras/MAPK cascade → neuronal differentiation, axonal growth, cholinergic neuron survival
- TrkB activation → PI3K/Akt → anti-apoptotic signaling; PLCγ → synaptic plasticity and LTP
- Also activates RET (GDNF receptor) and CNTFR pathways, providing multi-neurotrophin-like effects
- Downstream: Increased expression of synaptic proteins (synaptophysin, MAP-2, GAP-43)
Anti-amyloid mechanisms:
- Modulates APP (amyloid precursor protein) processing by shifting from amyloidogenic (β-secretase) to non-amyloidogenic (α-secretase) pathway (Rockenstein et al., PMID: 17080423)
- Reduces amyloid beta 1-42 production and oligomer formation
- Decreases tau hyperphosphorylation through GSK-3β inhibition
- Reduces amyloid plaque burden in transgenic AD mouse models
Neuroplasticity enhancement:
- Promotes dendritic branching and spine density in hippocampal and cortical neurons
- Enhances long-term potentiation (LTP) in hippocampal CA1 region
- Increases neurogenesis in the subventricular zone and dentate gyrus
- Upregulates synaptic vesicle proteins, enhancing neurotransmitter release efficiency
Anti-inflammatory and anti-apoptotic:
- Suppresses microglial activation and M1-polarized inflammatory responses
- Reduces pro-inflammatory cytokines: TNF-α, IL-1β, IL-6
- Inhibits calpain-mediated neuronal death (Hartbauer et al., PMID: 11311456)
- Reduces caspase-3 activation in ischemic and excitotoxic injury models
- Preserves BBB integrity by stabilizing tight junction proteins
Safety Profile
Cerebrolysin has demonstrated a favorable safety profile across extensive clinical use and clinical trials:
- Injection site reactions: Pain, redness, or swelling at the injection site are the most commonly reported adverse effects. IV administration is generally better tolerated than IM injection.
- Headache and dizziness: Mild headache and dizziness have been reported in some clinical trials, typically transient and self-limiting.
- Allergic reactions: Rare hypersensitivity reactions have been documented, including skin rash and urticaria. Anaphylaxis is extremely rare. Due to its porcine origin, it is contraindicated in individuals with known pork allergies.
- Seizure risk: Cerebrolysin should be used with caution in patients with epilepsy or seizure disorders, as isolated cases of seizure exacerbation have been reported, though causality has not been definitively established.
- Renal impairment: Caution is advised in patients with severe renal impairment, as the amino acid load requires renal clearance.
- Drug interactions: No significant drug interactions have been identified. Cerebrolysin can be used concomitantly with standard stroke, dementia, and TBI therapies.
- Contraindications: Epilepsy (relative), severe renal impairment, known hypersensitivity to porcine-derived products, pregnancy (insufficient data).
The safety record of Cerebrolysin is supported by post-marketing surveillance data from over 45 countries spanning more than three decades of clinical use.
Pharmacokinetic Profile
Cerebrolysin — Pharmacokinetic Curve
Intravenous, IntramuscularQuick Start
- Typical Dose
- 10-50mL depending on indication (stroke/TBI higher doses)
- Frequency
- Once daily for acute conditions; 5 days weekly for chronic conditions
- Route
- Intravenous, Intramuscular
- Cycle Length
- 7-30 days depending on condition (stroke/TBI 10-30 days, dementia 4 weeks)
- Storage
- Room temperature ≤25°C, protected from light in original carton - never freeze
Research Indications
Cognitive
Meta-analyses show modest cognitive improvements, though clinical significance remains debated.
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.
Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit.
Neuroprotection
Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement.
Multiple trials including CAPTAIN series confirm GCS/GOS improvements.
Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies.
Recovery
Some studies show enhanced recovery; results vary significantly between trials.
Early administration within 72 hours shows better outcomes than delayed treatment.
Research Protocols
subcutaneous Injection
Neurotrophic peptide mixture. Split doses exceeding 100 units into AM/PM administrations.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Week 1 | 20 mg | Once daily (single injection) | Week 1 |
| Week 2 | 24 mg | Split AM/PM | Week 2 |
| Week 3 | 28 mg | Split AM/PM | Week 3 |
| Full dose | 32 mg | Split AM/PM | Week 4+(Cycle 8-12 weeks, extendable to 16) |
Reconstitution Guide (60mg vial + 3mL BAC water)
- Wipe vial tops with alcohol swab
- Draw 3.0 mL bacteriostatic water into syringe
- Inject slowly down the inside wall of the peptide vial
- Gently swirl to dissolve — never shake
- Resulting concentration: 20 mg/mL
- For 20 mg dose: draw 100 units (1.00 mL)
- For 24 mg dose (split): draw 60 units AM (0.60 mL) + 60 units PM (0.60 mL)
- For 32 mg dose (split): draw 80 units AM (0.80 mL) + 80 units PM (0.80 mL)
- Store reconstituted vial refrigerated at 2-8°C
Interactions
Peptide Interactions
Both are neurotrophic agents used in Russian stroke protocols. Cerebrolysin provides exogenous neurotrophic peptides while Semax upregulates endogenous neurotrophin production. Sequential use (Cerebrolysin acute phase → Semax rehabilitation phase) is practiced clinically.
Safe combination with no significant interactions; both support cognitive function.
No interactions reported; may have synergistic cognitive effects in Alzheimer's treatment.
Both enhance neurotrophic factors; potential additive effects—start with lower doses.
What to Expect
What to Expect
Initial neuroprotective effects; possible mild side effects (dizziness, agitation)
Neurological improvements become apparent; cognitive function may begin to improve
Continued recovery; motor function improvements in stroke/TBI patients
Sustained benefits; cognitive enhancement plateaus in chronic conditions
Safety Profile
Common Side Effects
- Generally well tolerated
- Possible mild dizziness or agitation in early treatment
Contraindications
- Epilepsy
- Severe renal insufficiency
- History of severe allergic reactions to porcine products
Discontinue If
- Severe allergic reactions (anaphylaxis, severe rash)
- New onset seizure activity
- Significant cardiovascular events during administration
- Severe renal dysfunction or worsening kidney function
Quality Indicators
What to look for
- Clear amber solution from reputable source
- Room temperature storage ≤25°C
- Protected from light in original carton
- Authorized EVER Pharma distributor
Caution
- Some published studies have been retracted due to research misconduct; rely on independent meta-analyses
Red flags
- Frozen product or improper storage—never freeze
- Mixing with incompatible solutions (amino acids, vitamins, cardiovascular medications)
Frequently Asked Questions
References (25)
- [13]Rockenstein E, Torrance M, Mante M, et al Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation J Neurosci Res (2006)
- [14]Alvarez XA, Cacabelos R, Laredo M, et al A 24-week, double-blind, placebo-controlled study of Cerebrolysin in patients with Alzheimer's disease Eur J Neurol (2006)
- [5]
- [2]Nine-Trial Stroke Meta-Analysis - Positive Results (2017)
- [3]Conflicting Stroke Meta-Analysis - Neutral Results (2017)
- [4]TBI Systematic Review - Positive Outcomes (2023)
- [22]
- [23]Bornstein NM et al — Cerebrolysin for acute ischemic stroke: updated evidence from the E-COMPASS trial (2023)
- [24]
- [25]Plosker GL, Gauthier S — Cerebrolysin: an update on its use in Alzheimer's disease and vascular dementia (2023)
- [12]
- [1]
- [19]Chen CC, Wei ST, Tsaia SC, et al Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients Injury (2013)
- [6]
- [7]
- [8]
- [9]
- [11]
- [15]Hartbauer M, Hutter-Paier B, Windisch M Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons J Neural Transm (2001)
- [16]Windisch M, Gschanes A, Hutter-Paier B Neurotrophic activities and therapeutic experience with a brain derived peptide preparation J Neural Transm Suppl (2006)
- [21]Muresanu DF et al — Cerebrolysin in vascular dementia: an updated systematic review and meta-analysis (2022)
- [17]Heiss WD, Brainin M, Bornstein NM, et al Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial (CASTA) Stroke (2012)
- [18]Muresanu DF, Heiss WD, Hoemberg V, et al Cerebrolysin and recovery after stroke (CARS) Ann Neurol (2016)
- [20]Zhang C, Chopp M, Cui Y, et al Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke J Neurosci Res (2010)
- [10]
Cartalax
Cartalax (AED) is a synthetic tripeptide bioregulator that modulates fibroblast function across multiple tissues, studied for its geroprotective effects on skin, cartilage, and kidney tissue. Research demonstrates it increases cell proliferation and reduces senescence markers through regulation of Ki-67, p53, and SIRT-6 pathways.
Cerluten
Cerluten is a complex peptide bioregulator preparation derived from brain tissue, developed at the St. Petersburg Institute of Bioregulation and Gerontology for research in cognitive aging, neurodegeneration, and cerebral function. Distinguished from cortagen (AEDP), which is a single tetrapeptide CNS bioregulator.